All Videos Channels
  2. ( -0766) Is There Light For Democrats At the End of the Trump Tunnel - RFK Jr., Light Disinfectant, Chlorine Dioxide, Photodynamic Compounds [PDC's], Etc.

    ( -0766) Is There Light For Democrats At the End of the Trump Tunnel - RFK Jr., Light Disinfectant, Chlorine Dioxide, Photodynamic Compounds [PDC's], Etc.

    7
    0
    361
  4. Innovation Needed: Ablative Techniques in Cancer Therapy

    Innovation Needed: Ablative Techniques in Cancer Therapy

    38
  6. Photodynamic Therapy Heating Treatment

    Photodynamic Therapy Heating Treatment

    25
  7. Soligenix: Illuminating the Future of Rare Disease Therapies

    Soligenix: Illuminating the Future of Rare Disease Therapies

    6
  9. Soligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases

    Soligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases

    3
    0
    6
  12. Cutting Edge Techniques for Cancer Treatment with Dr. Michael Karlfeldt | Conners Clinic Live #40

    Cutting Edge Techniques for Cancer Treatment with Dr. Michael Karlfeldt | Conners Clinic Live #40

    15
    1
  13. September 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment of Cutaneous T-Cell Lymphoma and Psoriasis

    September 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment of Cutaneous T-Cell Lymphoma and Psoriasis

    23
  15. May 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment for Lymphoma and Psoriasis

    May 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment for Lymphoma and Psoriasis

    11
  16. Revolutionizing Rare Disease Treatment: Introducing Soligenix's Breakthrough HyBryte™

    Revolutionizing Rare Disease Treatment: Introducing Soligenix's Breakthrough HyBryte™

    12
  17. HyBryte™ by Soligenix: Transforming Cutaneous T-Cell Lymphoma Treatment

    HyBryte™ by Soligenix: Transforming Cutaneous T-Cell Lymphoma Treatment

    17
  18. Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

    Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

    3